Establishment Labs price target raised to $65 from $50 at Mizuho

Mizuho raised the firm’s price target on Establishment Labs to $65 from $50 and keeps a Buy rating on the shares. The target increase reflects the potential for U.S. Motiva to receive FDA clearance by mid-year following the final agency site inspection, the analyst tells investors in a research note. Citing Motiva’s “demonstrated safety superiority versus competition,” the firm assigns an 85% probability of success towards a favorable outcome. It reiterates Establishment Labs as a top small-cap pick into the “favorable near-term setup.”